Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abdakibart - Avalo Therapeutics

Next Previous
Drug Profile

Abdakibart - Avalo Therapeutics

Alternative Names: AVTX-009; FL-101; Fl101; IL-1β antibody - Eli Lilly; LY-2189102

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Avalo Therapeutics; Eli Lilly and Company; Flame Biosciences
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Cardiovascular therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 1beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa
  • Discontinued Cardiovascular disorders; Non-small cell lung cancer; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 06 Aug 2026 Avalo Therapeutics plans a registrational phase II trial in Hidradenitis suppurativa in the first half of 2027
  • 05 May 2026 Adverse events and efficacy data from a phase II LOTUS trial in Hidradenitis suppurativa released by Avalo Therapeutics
  • 17 Mar 2026 Avalo Therapeutics completes the phase II LOTUS trial in Hidradenitis suppurativa in USA, Australia, Canada, Bulgaria, Czech Republic, France, Germany, Greece, Italy, Poland, Slovakia, Spain and Turkey (SC, Injection) (NCT06603077)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top